Ye P - Search Results

1

Association of serum lipids with arterial stiffness in a population-based study in Beijing.

Wang F, Ye P, Luo L, Xiao W, Qi L, Bian S, Wu H, Sheng L, Xiao T, Xu R. Wang F, et al. Among authors: ye p. Eur J Clin Invest. 2011 Sep;41(9):929-36. doi: 10.1111/j.1365-2362.2011.02481.x. Epub 2011 Feb 14. Eur J Clin Invest. 2011. PMID: 21314825

2

[Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro].

Sheng L, Ye P, Liu YX. Sheng L, et al. Among authors: ye p. Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1080-4. Zhonghua Xin Xue Guan Bing Za Zhi. 2005. PMID: 16563274 Chinese.

3

Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo.

Ye P, Sheng L, Zhang C, Liu Y. Ye P, et al. J Pharm Pharm Sci. 2006;9(3):365-75. J Pharm Pharm Sci. 2006. PMID: 17207419 Free article.

4

Effect of pioglitazone on the expression of inflammatory cytokines in attenuating rat cardiomyocyte hypertrophy.

Ye P, Yang W, Wu SM, Sheng L. Ye P, et al. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):691-6. doi: 10.1358/mf.2006.28.10.1037500. Methods Find Exp Clin Pharmacol. 2006. PMID: 17235413 Free article.

5

Inhibition of plasminogen activator inhibitor type-1 expression in HepG2 cells by fenofibrate may be associated with Smad signaling.

Chen J, Ye P, Liu YX, Sheng L, Han CG, He YL. Chen J, et al. Among authors: ye p. Clin Chim Acta. 2008 Jan;387(1-2):18-23. doi: 10.1016/j.cca.2007.08.009. Epub 2007 Aug 31. Clin Chim Acta. 2008. PMID: 17931611

6

Correlation of body composition with cardiac function and arterial compliance.

Zeng Q, Sun XN, Fan L, Ye P. Zeng Q, et al. Among authors: ye p. Clin Exp Pharmacol Physiol. 2008 Jan;35(1):78-82. doi: 10.1111/j.1440-1681.2007.04749.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18047632

7

Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro.

Sheng L, Ye P, Liu YX, Han CG, Zhang ZY. Sheng L, et al. Among authors: ye p. Clin Exp Hypertens. 2008 Feb;30(2):109-19. doi: 10.1080/10641960801945840. Clin Exp Hypertens. 2008. PMID: 18293166 Free article.

8

Effect of xuezhikang on alpha1- and beta2-microglobulin in patients with essential hypertension.

Ye P, Wu C, Sheng L, Li H. Ye P, et al. J Hum Hypertens. 2009 Jan;23(1):72-4. doi: 10.1038/jhh.2008.97. Epub 2008 Jul 31. J Hum Hypertens. 2009. PMID: 18668126 Clinical Trial. No abstract available.

9

Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension.

Ye P, Wu CE, Sheng L, Li H. Ye P, et al. J Altern Complement Med. 2009 Jul;15(7):719-25. doi: 10.1089/acm.2008.0599. J Altern Complement Med. 2009. PMID: 19552598 Clinical Trial.

10

[In vivo tracing of transplanted bone marrow mesenchymal stem cells with bioluminescence imaging].

Bian SY, Gai LY, Ye P, Yang YF, Wang H, Guo ZK, Wang LS. Bian SY, et al. Among authors: ye p. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Oct;17(5):1307-11. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009. PMID: 19840472 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,088 results

Search Page

Filters